LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Search

Abbott Laboratories

Затворен

СекторЗдравеопазване

129.13 0.34

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

128.86

Максимум

129.35

Ключови измерители

By Trading Economics

Приходи

-135M

1.6B

Продажби

227M

11B

P/E

Средно за сектора

15.979

79.874

EPS

1.3

Дивидентна доходност

1.84

Марж на печалбата

14.46

Служители

114,000

EBITDA

-33M

3B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+14.55% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

1.84%

2.31%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-7.3B

221B

Предишно отваряне

128.79

Предишно затваряне

129.13

Настроения в новините

By Acuity

25%

75%

55 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Abbott Laboratories Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.11.2025 г., 13:14 ч. UTC

Придобивния, сливания и поглъщания

Correction to Abbott to Acquire Exact Sciences for $21 Billion Article

20.11.2025 г., 13:11 ч. UTC

Придобивния, сливания и поглъщания

Abbott to Acquire Exact Sciences for $21 Billion -- Update

20.11.2025 г., 12:55 ч. UTC

Придобивния, сливания и поглъщания

Abbott to Acquire Exact Sciences for $21 Billion

20.11.2025 г., 21:23 ч. UTC

Печалби
Придобивния, сливания и поглъщания

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20.11.2025 г., 16:51 ч. UTC

Придобивния, сливания и поглъщания

Abbott Laboratories Will Buy Cologuard Maker Exact Sciences for $21 Billion -- Barrons.com

20.11.2025 г., 15:08 ч. UTC

Придобивния, сливания и поглъщания

Abbott to Acquire Exact Sciences for $21 Billion -- 4th Update

20.11.2025 г., 14:39 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Abbott and Exact Sciences Should Make a Good Fit -- Market Talk

20.11.2025 г., 14:30 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Exact Sciences Should Give Abbott's Diagnostics Business a Needed Boost -- Market Talk

20.11.2025 г., 13:54 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Palo Alto Networks, Alphabet, and More -- Barrons.com

20.11.2025 г., 13:51 ч. UTC

Придобивния, сливания и поглъщания

Abbott to Acquire Exact Sciences for $21 Billion -- 3rd Update

20.11.2025 г., 13:25 ч. UTC

Придобивния, сливания и поглъщания

Abbott to Acquire Exact Sciences for $21 Billion -- 2nd Update

20.11.2025 г., 13:24 ч. UTC

Придобивния, сливания и поглъщания

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

20.11.2025 г., 12:59 ч. UTC

Придобивния, сливания и поглъщания

Correction to Abbott to Acquire Exact Sciences for $21B Article

20.11.2025 г., 12:58 ч. UTC

Придобивния, сливания и поглъщания

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

20.11.2025 г., 12:56 ч. UTC

Придобивния, сливания и поглъщания

Abbott to Acquire Exact Sciences for $21B -- Update

20.11.2025 г., 12:54 ч. UTC

Придобивния, сливания и поглъщания

Abbott Labs: Expect to Maintain Investment-Grade Credit Rating >ABT EXAS

20.11.2025 г., 12:53 ч. UTC

Придобивния, сливания и поглъщания

Abbott Labs to Fund Exact Sciences Deal With Cash on Hand, Debt Financing >ABT EXAS

20.11.2025 г., 12:53 ч. UTC

Придобивния, сливания и поглъщания

Abbott Labs Sees Exact Sciences Deal Adding to Adjusted EPS in 2028, Beyond >ABT EXAS

20.11.2025 г., 12:53 ч. UTC

Придобивния, сливания и поглъщания

Abbott Labs Sees Exact Sciences Deal Cutting Adjusted EPS by 20c in 2026, 16c in 2027 >ABT EXAS

20.11.2025 г., 12:52 ч. UTC

Придобивния, сливания и поглъщания

Abbott Labs Sees at Least $100 Million Annual Pretax Synergies From Exact Sciences Deal by 2028 >ABT EXAS

20.11.2025 г., 12:46 ч. UTC

Придобивния, сливания и поглъщания

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

20.11.2025 г., 12:40 ч. UTC

Придобивния, сливания и поглъщания

Abbott to Acquire Exact Sciences for $21B

20.11.2025 г., 12:33 ч. UTC

Придобивния, сливания и поглъщания

Abbott Labs: Exact Sciences Deal Has Enterprise Value of About $23 Billion >ABT EXAS

20.11.2025 г., 12:33 ч. UTC

Придобивния, сливания и поглъщания

Exact Sciences to Be Acquired for $105/Share; Closed Wednesday at $86.18 >ABT EXAS

20.11.2025 г., 12:32 ч. UTC

Придобивния, сливания и поглъщания

Abbott Labs Sees Acquisition Immediately Adding to Revenue Growth, Gross Margin >ABT EXAS

20.11.2025 г., 12:31 ч. UTC

Придобивния, сливания и поглъщания

Abbott Labs: Exact Sciences Deal Has Total Equity Value of About $21 Billion >ABT EXAS

20.11.2025 г., 12:30 ч. UTC

Придобивния, сливания и поглъщания

Abbott to Buy Exact Sciences for $105/Share >ABT EXAS

20.11.2025 г., 12:30 ч. UTC

Придобивния, сливания и поглъщания

Abbott To Acquire Exact Sciences, A Leader In Large And Fast-growing Cancer Screening And Precision Oncology Diagnostics Segments >ABT

19.11.2025 г., 21:27 ч. UTC

Придобивния, сливания и поглъщания

Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories -- Barrons.com

30.10.2025 г., 12:38 ч. UTC

Печалби

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Abbott Laboratories Прогноза

Ценова цел

By TipRanks

14.55% нагоре

12-месечна прогноза

Среден 147.24 USD  14.55%

Висок 162 USD

Нисък 136 USD

Според 19 анализатори от Wall Street, предложили 12-месечна ценова цел за Abbott Laboratories през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

19 ratings

17

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

132.82 / 134.43Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Neutral Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

55 / 374 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
help-icon Live chat